Attached files
| file | filename |
|---|---|
| EX-31.2 - EX-31.2 - Prevail Therapeutics Inc. | prvl-ex312_7.htm |
| EX-31.1 - EX-31.1 - Prevail Therapeutics Inc. | prvl-ex311_8.htm |
| EX-23.1 - EX-23.1 - Prevail Therapeutics Inc. | prvl-ex231_816.htm |
| EX-10.10 - EX-10.10 - Prevail Therapeutics Inc. | prvl-ex1010_817.htm |
| EX-10.8 - EX-10.8 - Prevail Therapeutics Inc. | prvl-ex108_629.htm |
| EX-4.3 - EX-4.3 - Prevail Therapeutics Inc. | prvl-ex43_628.htm |
| 10-K - 10-K - Prevail Therapeutics Inc. | prvl-10k_20191231.htm |
Exhibit 32.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Prevail Therapeutics, Inc. (the “Company”) on Form 10-K for the period ending December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
|
|
(1) |
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
|
Date: March 26, 2020 |
|
By: |
/s/ Asa Abeliovich, M.D., Ph.D. |
|
|
|
|
Asa Abeliovich, M.D., Ph.D. |
|
|
|
|
President and Chief Executive Officer (Principal Executive Officer) |
In connection with the Annual Report of Prevail Therapeutics, Inc. (the “Company”) on Form 10-K for the period ending December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
|
|
(1) |
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
|
Date: March 26, 2020 |
|
By: |
/s/ Brett Kaplan, M.D. |
|
|
|
|
Brett Kaplan, M.D. |
|
|
|
|
Chief Financial Officer (Principal Financial and Accounting Officer) |